Compensated liver cirrhosis: Natural course and disease-modifying strategies

Table 2 Impact of etiological treatment on regression of liver cirrhosis

Ref.	Study design	Drug/duration	Patients, n	Baseline LC	Main results
Dienstag et al[26], 2003	Prospective, partially randomised	Lamivudin/3 yr	63 CHB	11	LC regressed in 8 of 11 patients (73%)
Hadziyannis et al[27], 2006	Prospective	Adefovir dipivoxil, up to 240 wk	125 CHB	4	58% had reversal of bridging fibrosis/cirrhosis; 3 of 4 LC patients had reversal
Marcellin et al[29], 2013	Randomised trial	TDF/adefovir for 48 wk then open-label TDF	641 CHB	96	71 of 96 (74%) became non-cirrhotic at 5 yr
Poynard et al[52], 2002	Pooled data from RCTs	IFN/PEG-IFN + RBV	3010 CHC	153	The reversal of LC was observed in 75 patients (49%)
Mauro et al[53], 2018	Retrospective	DAAs/IFN + RBV	112 HCV-infected LT recipients	37	Regression of fibrosis in 43% of LC (16/37)
Lassailly et al[55], 2020	Prospective	Bariatric surgery	180 obese NASH	9	At 5 yr, fibrosis regression was seen in 68% of advanced fibrosis and 33% of patients had reversal of LC
Sanyal et al[54], 2022	Data from two RCTs	Simtuzumab or selonsertib or placebo	1135 NASH patients, 709 (62%) had Ishak stage 6 fibrosis	709	LC regression occurred in 16% (176/1135). Drugs were not better than placebo
Dufour et al[64], 1997	Retrospective	Immunosuppressant	8 AIH cirrhosis	8	LC regressed in all
Czaja et al[63], 2004	Retrospective	Corticosteroid	87 AIH	14	LC regressed in 4 of 14 patients
Bardou-Jacquet et al[66], 2020	Retrospective	Venesection	106 patients with haemochromatosis	66	LC regressed in 15 of 66 (23%) during median follow-up of 9.5 yr

AIH: Autoimmune hepatitis; CHB: Chronic hepatitis B; CHC: Chronic hepatitis C; DAAs: Direct-acting antivirals; HCV: Hepatitis C virus; IFN: Interferon; LC: Liver cirrhosis; LT: Liver transplantation; NASH: Nonalcoholic steatohepatitis; PEG-IFN: Pegylated interferon; RBV: Ribavirin; RCT: Randomised controlled trial; TDF: Tenofovir disoproxil fumarate.